Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth

Journal of Biological Chemistry

Volumn 287, Issue 33, 2012, Pages 28180-28194

  Kelly, Geraldine M ^a   Buckley, Deirdre A ^a   Kiely, Patrick A ^a,c   Adams, David R ^b   O'Connor, Rosemary ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHOSPHORYLATION; C TERMINUS; C-TERMINAL TAIL; CELL SURFACE EXPRESSION; CRYSTALLOGRAPHIC STRUCTURE; IN-VITRO; INSULIN-LIKE GROWTH FACTOR-I; KINASE ACTIVITY; KINASE DOMAINS; KNOCK OUTS; POTENTIAL PROTEINS; RECEPTOR TRAFFICKING; REGULATORY FUNCTIONS; SERINE PHOSPHORYLATION; STRUCTURAL TRANSITIONS; TARGET OF RAPAMYCIN;

AMINO ACIDS; CELL GROWTH; CELL MEMBRANES; GROWTH KINETICS; INSULIN; PHOSPHORYLATION;

ENZYMES;

GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MUTANT PROTEIN; PROTEIN KINASE B; SERINE; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL SIZE; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IN VITRO STUDY; INTERNALIZATION; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RECEPTOR, IGF TYPE 1; SERINE; SIGNAL TRANSDUCTION;

EID: 84865047669     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.385757     Document Type: Article

References (59)

1. Baserga, R. (2007) Is cell size important? Cell Cycle 6, 814-816
2. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J., and Efstratiadis, A. (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72
3. O'Connor, R. (2003) Regulation of IGF-I receptor signaling in tumor cells. Horm. Metab. Res. 35, 771-777
4. Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., and Levine, A. J. (2007) The regulation of AMPKβ1, TSC2, and PTEN expression by p53. Stress, cell, and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67, 3043-3053
5. Gualberto, A., and Pollak, M. (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-3021
6. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., and Chen, E. (1986) Insulin-like growth factor I receptor primary structure. Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 5, 2503-2512
7. Favelyukis, S., Till, J. H., Hubbard, S. R., and Miller, W. T. (2001) Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8, 1058-1063
8. O'Connor, R., Kauffmann-Zeh, A., Liu, Y., Lehar, S., Evan, G. I., Baserga, R., and Blättler, W. A. (1997) Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol. 17, 427-435
9. Chen, H., Yan, G. C., and Gishizky, M. L. (1998) Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors. Cell Growth Differ. 9, 939-947
10. Li, S., Termini, J., Hayward, A., Siddle, K., Zick, Y., Koval, A., LeRoith, D., and Fujita-Yamaguchi, Y. (1998) The carboxyl-terminal domain of insulin-like growth factor-I receptor interacts with the insulin receptor and activates its protein-tyrosine kinase. FEBS Lett. 421, 45-49
11. Hongo, A., D'Ambrosio, C., Miura, M., Morrione, A., and Baserga, R. (1996) Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 12, 1231-1238
12. Li, S., Resnicoff, M., and Baserga, R. (1996) Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J. Biol. Chem. 271, 12254-12260
13. Esposito, D. L., Blakesley, V. A., Koval, A. P., Scrimgeour, A. G., and LeRoith, D. (1997) Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 138, 2979-2988
14. Blakesley, V. A., Koval, A. P., Stannard, B. S., Scrimgeour, A., and LeRoith, D. (1998) Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J. Biol. Chem. 273, 18411-18422
15. Brodt, P., Fallavollita, L., Khatib, A. M., Samani, A. A., and Zhang, D. (2001) Cooperative regulation of the invasive and metastatic phenotypes by different domains of the type I insulin-like growth factor receptor β subunit. J. Biol. Chem. 276, 33608-33615
16. Kiely, P. A., Leahy, M., O'Gorman, D., and O'Connor, R. (2005) RACK1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251. J. Biol. Chem. 280, 7624-7633
17. Surmacz, E., Sell, C., Swantek, J., Kato, H., Roberts, C. T., Jr., LeRoith, D., and Baserga, R. (1995) Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp. Cell Res. 218, 370-380
18. Hongo, A., Yumet, G., Resnicoff, M., Romano, G., O'Connor, R., and Baserga, R. (1998) Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristoylated COOH terminus of the insulin-like growth factor I receptor. Cancer Res. 58, 2477-2484
19. Liu, Y., Lehar, S., Corvi, C., Payne, G., and O'Connor, R. (1998) Expression of the insulin-like growth factor I receptor C terminus as a myristoylated protein leads to induction of apoptosis in tumor cells. Cancer Res. 58, 570-576
20. Kiely, P. A., Sant, A., and O'Connor, R. (2002) RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J. Biol. Chem. 277, 22581-22589
21. Zhang, W., Zong, C. S., Hermanto, U., Lopez-Bergami, P., Ronai, Z., and Wang, L. H. (2006) RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol. Cell. Biol. 26, 413-424
22. Pautsch, A., Zoephel, A., Ahorn, H., Spevak, W., Hauptmann, R., and Nar, H. (2001) Crystal structure of bisphosphorylated IGF-1 receptor kinase. Insight into domain movements upon kinase activation. Structure 9, 955-965
23. Munshi, S., Kornienko, M., Hall, D. L., Reid, J. C., Waxman, L., Stirdivant, S. M., Darke, P. L., and Kuo, L. C. (2002) Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J. Biol. Chem. 277, 38797-38802
24. Munshi, S., Hall, D. L., Kornienko, M., Darke, P. L., and Kuo, L. C. (2003) Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 Å resolution. Acta Crystallogr. D Biol. Crystallogr. 59, 1725-1730
25. Velaparthi, U., Wittman, M., Liu, P., Stoffan, K., Zimmermann, K., Sang, X., Carboni, J., Li, A., Attar, R., Gottardis, M., Greer, A., Chang, C. Y., Jacobsen, B. L., Sack, J. S., Sun, Y., Langley, D. R., Balasubramanian, B., and Vyas, D. (2007) Discovery and initial SAR of 3-(1H-benzo[D[rsqb]imidazol-2-yl) pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R). Bioorg. Med. Chem. Lett. 17, 2317-2321
26. Mayer, S. C., Banker, A. L., Boschelli, F., Di, L., Johnson, M., Kenny, C. H., Krishnamurthy, G., Kutterer, K., Moy, F., Petusky, S., Ravi, M., Tkach, D., Tsou, H. R., and Xu, W. (2008) Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 18, 3641-3645
27. Wu, J., Li, W., Craddock, B. P., Foreman, K. W., Mulvihill, M. J., Ji, Q. S., Miller, W. T., and Hubbard, S. R. (2008) Small molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J. 27, 1985-1994
28. Miller, L. M., Mayer, S. C., Berger, D. M., Boschelli, D. H., Boschelli, F., Di, L., Du, X., Dutia, M., Floyd, M. B., Johnson, M., Kenny, C. H., Krishnamurthy, G., Moy, F., Petusky, S., Tkach, D., Torres, N., Wu, B., and Xu, W. (2009) Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 19, 62-66
29. Wittman, M. D., Carboni, J. M., Yang, Z., Lee, F. Y., Antman, M., Attar, R., Balimane, P., Chang, C., Chen, C., Discenza, L., Frennesson, D., Gottardis, M. M., Greer, A., Hurlburt, W., Johnson, W., Langley, D. R., Li, A., Li, J., Liu, P., Mastalerz, H., Mathur, A., Menard, K., Patel, K., Sack, J., Sang, X., Saulnier, M., Smith, D., Stefanski, K., Trainor, G., Velaparthi, U., Zhang, G., Zimmermann, K., and Vyas, D. M. (2009) Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem. 52, 7360-7363
30. Nemecek, C., Metz, W. A., Wentzler, S., Ding, F. X., Venot, C., Souaille, C., Dagallier, A., Maignan, S., Guilloteau, J. P., Bernard, F., Henry, A., Grapinet, S., and Lesuisse, D. (2010) Design of potent IGF1-R inhibitors related to bis-aza-indoles. Chem. Biol. Drug Des. 76, 100-106
31. Sampognaro, A. J., Wittman, M. D., Carboni, J. M., Chang, C., Greer, A. F., Hurlburt, W. W., Sack, J. S., and Vyas, D. M. (2010) Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg. Med. Chem. Lett. 20, 5027-5030
32. Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., Rubin, R., Efstratiadis, A., and Baserga, R. (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14, 3604-3612
33. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000) Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406, 86-90
34. Adams, D. R., Ron, D., and Kiely, P. A. (2011) RACK1, a multifaceted scaffolding protein. Structure and function. Cell Commun. Signal. 9, 22
35. Hermanto, U., Zong, C. S., Li, W., and Wang, L. H. (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol. Cell. Biol. 22, 2345-2365
36. Obenauer, J. C., Cantley, L. C., and Yaffe, M. B. (2003) Scansite 2.0. Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31, 3635-3641
37. Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., and Pearl, L. H. (2001) Crystal structure of glycogen synthase kinase 3β. Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732
38. Frame, S., Cohen, P., and Biondi, R. M. (2001) A common phosphate-binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327
39. Kiely, P. A., Baillie, G. S., Barrett, R., Buckley, D. A., Adams, D. R., Houslay, M. D., and O'Connor, R. (2009) Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. J. Biol. Chem. 284, 20263-20274
40. Farghaian, H., Turnley, A. M., Sutherland, C., and Cole, A. R. (2011) Bioinformatic prediction and confirmation of β-adducin as a novel substrate of glycogen synthase kinase 3. J. Biol. Chem. 286, 25274-25283
41. Du, J., Wei, Y., Liu, L., Wang, Y., Khairova, R., Blumenthal, R., Tragon, T., Hunsberger, J. G., Machado-Vieira, R., Drevets, W., Wang, Y. T., and Manji, H. K. (2010) A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors. Proc. Natl. Acad. Sci. U.S.A. 107, 11573-11578
42. Chen, P., Gu, Z., Liu, W., and Yan, Z. (2007) Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 72, 40-51
43. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754
44. Bae, J. H., Lew, E. D., Yuzawa, S., Tomé, F., Lax, I., and Schlessinger, J. (2009) The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell 138, 514-524
45. Shewchuk, L. M., Hassell, A. M., Ellis, B., Holmes, W. D., Davis, R., Horne, E. L., Kadwell, S. H., McKee, D. D., and Moore, J. T. (2000) Structure of the Tie2 RTK domain. Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8, 1105-1113
46. Niu, X. L., Peters, K. G., and Kontos, C. D. (2002) Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J. Biol. Chem. 277, 31768-31773
47. Blakesley, V. A., Kalebic, T., Helman, L. J., Stannard, B., Faria, T. N., Roberts, C. T., Jr., and LeRoith, D. (1996) Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxyl terminus of the IGF-I receptor. Endocrinology 137, 410-417
48. Leahy, M., Lyons, A., Krause, D., and O'Connor, R. (2004) Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J. Biol. Chem. 279, 18306-18313
49. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. (1996) Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 272, 1023-1026
50. Frame, S., and Cohen, P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16
51. Welsh, G. I., Miller, C. M., Loughlin, A. J., Price, N. T., and Proud, C. G. (1998) Regulation of eukaryotic initiation factor eIF2B. Glycogen synthase kinase-3 phosphorylates a conserved serine that undergoes dephosphorylation in response to insulin. FEBS Lett. 421, 125-130
52. Suzuki, Y., Lanner, C., Kim, J. H., Vilardo, P. G., Zhang, H., Yang, J., Cooper, L. D., Steele, M., Kennedy, A., Bock, C. B., Scrimgeour, A., Lawrence, J. C., Jr., and DePaoli-Roach, A. A. (2001) Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol. Cell. Biol. 21, 2683-2694
53. Force, T., and Woodgett, J. R. (2009) Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J. Biol. Chem. 284, 9643-9647
54. Kerkela, R., Kockeritz, L., Macaulay, K., Zhou, J., Doble, B. W., Beahm, C., Greytak, S., Woulfe, K., Trivedi, C. M., Woodgett, J. R., Epstein, J. A., Force, T., and Huggins, G. S. (2008) Deletion of GSK-3β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Invest. 118, 3609-3618
55. Voskas, D., Ling, L. S., and Woodgett, J. R. (2010) Does GSK-3 provide a shortcut for PI3K activation of Wnt signaling? Biol. Rep. 2, 82
56. Ludwig, T., Eggenschwiler, J., Fisher, P., D'Ercole, A. J., Davenport, M. L., and Efstratiadis, A. (1996) Dev. Biol. 177, 517-535
57. Kiely, P. A., O'Gorman, D., Luong, K., Ron, D., and O'Connor, R. (2006) Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and β1 integrin to promote cell migration. Mol. Cell. Biol. 26, 4041-4051
58. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw, P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E., DeFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M. H., Khoo, S. K., Teh, B. T., Yuen, S. Y., Leung, S. Y., Wooster, R., Futreal, P. A., and Stratton, M. R. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158
59. Craddock, B. P., and Miller, W. T. (2012) Effects of somatic mutations in the C terminus of insulin-like growth factor I receptor on activity and signaling. J. Signal. Trans. 20121-20127